VEGFA and systemic sclerosis: Nintedanib, a tyrosine kinase inhibitor (TKI) targeting fibroblast growth factor (FGF) receptor, PDGF receptor, and vascular endothelial growth factor (VEGF) receptor, has been recently approved for the treatment of SSc-ILD by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), following the results of the phase III SENSCIS trial [80].